EXUMA Biotech to Participate in the Upcoming Baird Global Healthcare Investor Conference in September 2022
08 Sep 2022
WEST PALM BEACH, Fla., Sept. 8, 2022 /PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced today that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of the annual Baird Global Healthcare Conference in New York. Dr. Wade will be available for one-on-one investor meetings during the conference. Please contact your Baird representative to schedule a meeting with Greg.
About EXUMA Biotech
EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cell and gene therapies for the treatment of solid and hematological malignancies. The company is leveraging a global R&D footprint to advance product candidates designed to have reduced cost and complexity with increased safety, efficacy, and scalability compared to existing chimeric antigen receptor (CAR) therapies. For more information, visit exumabio.com and connect with us on LinkedIn and Twitter (@ExumaBiotech).
Contact:
Gregory R. Wade, Ph.D.
Chief Business Officer & Head of Finance
gwade@exumabio.com
View original content to download multimedia:
SOURCE EXUMA Biotech Corp.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.